Search PubMed⌕ Search

Biomedical subjects

E Gitsch

Publications and source records attributed to E Gitsch.

At least 55 records · Page 3Linked to original sources
PubMed1985

[Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].

From June 1980 to December 1982 164 patients with ovarian cancer stage III and IV were randomized into the three-legged Austrian Ovarian Cancer Study. A new polychemotherapy, known as the "changing-scheme" (adriamycin/cisplatinum--vincristine/cyclophosphamide--high dose methotrexate), developed in Vienna, was compared with adriamycin/cyclophosphamide and adriamycin/cisplatinum. The risk factors were stratified by means of special computer-assisted randomization. The first study evaluation in 1982 showed a significant advantage for the changing-scheme with regard to recurrence-free interval and survival (Mantel test: p less than 0.01, Breslow test: p less than 0.03). No difference was found between the combinations of adriamycin/cyclophosphamide and adriamycin/cisplatinum. At the second study evaluation in June 1984 the differences previously observed were no longe present to the same significant extent. The changing-scheme continued to be superior for the subgroups of patients with highly differentiated tumors, without ascites, with larger postoperative tumor burden and with liver metastases. The use of this therapy is be recommended for women with advanced ovarian cancer, especially in consideration of the much lower toxicity caused by the less frequent cisplatinum administrations as compared to the adriamycin/cisplatinum combination.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1985

[Results of the 1st Austrian ovarian cancer study: prospective randomized comparison of a new sequential chemotherapy with 2 standard regimens in 150 stage III and IV patients].

The results of a randomized trial of 150 patients, who were either treated with 6 cycles of adriamycin (40 mg/m2) and cyclophosphamide (500 mg/m2) or a combination of adriamycin (40 mg/m2) and cis-platin (50 mg/m2) or a combination of a cross-over regime: adriamycin (40 mg/my day 1), cisplatin (100 mg/my day 2), vincristine (1.4 mg/m2 day 28), cyclophosphamide (1.500 mg/m2 day 25), methotrexate (1.000 mg/m2 day 56) (a total of 2 cycles) are summarized forthwith. The longest mean survival times were obtained in the cross-over regime (19.6 months). The patients with highly differentiated tumors benefited most from this type of chemotherapy: mean survival time 26.3 months as opposed to 17.6 months.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1985

Prostacyclin does not influence placental blood pool in vivo.

In 20 healthy pregnant women placental blood pool was estimated by means of placental scintigrams before, during and after infusion of either prostacyclin (PGI2) or placebo for 10 min to study the effect of PGI2 on the local regulation of uterine blood flow. There was no difference in the mean number of counts between the PGI2- and the placebo-treated group. Therefore no effect of PGI2 on uteroplacental blood pool could be detected in healthy gravidae.

Adult↗
PubMed1984

[Significance of ovulatory age in the pathogenesis of ovarian cancer].

The impact of several parameters influencing ovulation upon the epidemiology of ovarian cancer was assessed retrospectively on 129 patients. The same number of women with other gynaecological diagnoses was used as controls. "Ovulatory age" was significantly higher in patients than in controls. Relative risk to develop ovarian cancer decreased with the increase of "protected time". Blood-group A was found considerably more frequently, blood-group 0 less frequently in patients than in the normal population.

ABO Blood-Group System↗
PubMed1984

[Indications and technic of operative vaginal delivery in vertex presentation].

In operative vaginal delivery in vertex presentation we pay attention to a separation in the indication for using a forceps or using a vacuumextractor. A delivery with a vacuumextractor is recommendable only in a flexion of the fetal head, in a low obstetrical resistance and with slow tractions. A delivery with a forceps is recommendable even in a deflexion of the fetal head, in a high obstetrical resistance and in fetal distress situations. A comparison in 2 collectives, each of a time period of 5 years, shows an interesting difference. In collective 1 (1963 to 1967) the frequency of forceps deliveries was 2.2% and of vacuumdeliveries was 3.2%. In collective 2 (1978 to 1982) the frequency of forcepsdeliveries was 4.1% and of vacuumdeliveries was 0.4%. Caused by a separation of the indication and by a consequent fetal monitoring there was an improvement in fetal and maternal morbidity and mortality. Using a handle in forceps delivery the procedure is more easy and less harmful for the baby.

Extraction, Obstetrical↗
PubMed1984

Intraoperative lymph scintigraphy during radical surgery for cervical cancer.

Intraoperative lymph scintigraphy during radical surgery for cervical cancer was developed in the course of a program covering three periods. During the last period technetium-99m antimony sulfide has been used to visualize pelvic lymph nodes. Surgery is done with a modified gamma camera serving as an operating table. This ensures intraoperative monitoring and greater thoroughness of lymphadenectomy. The introduction of the technique has improved the rate of total lymphadenectomies and has increased both the yields of involved nodes and the 3-yr survival rates.

Antimony↗
PubMed1984

Control by radioisotope labeling tissue of complete or incomplete lymphadenectomy.

Nuclide-assisted radical surgery for cervical carcinoma was developed in three stages. The improved rate of lymphnode removal thus obtained was associated with a reduced mortality from recurrent tumor both in cases with and without lymphnode involvement. Results in the third period under review suggest that patients undergoing incomplete lymphadenectomy have a significantly poorer prognosis than those with complete removal lymphnodes.

Antimony↗
PubMed1983

[Therapy of the surgical menopause syndrome with depot medroxyprogesterone acetate and its objective evaluation testing the reaction of the anterior pituitary gland to stimulation with gonadotropin-releasing hormone].

A randomized placebo-controlled double-blind study was conducted to evaluate the effect of 150 mg depot medroxyprogesterone acetate (DMPA) intramuscularly on the surgical menopause syndrome. The clinical material consisted of 30 hysterectomized and bilaterally salpingo-oophorectomized women between 38 and 54 years of age. Inclusion criteria were regular menstrual cycles until operation, the appearance of frequent vasomotor flushes (VMF) after operation, and serum FSH levels exceeding 20 mIU per ml. Since it has been shown that an increase in "LH pulses" and basal serum LH levels constitute objective parameters of VMF, determination of LH was chosen as biochemical criterion of therapeutic efficacy. DMPA was proven to reduce basal serum LH levels owing to its suppressive effect on the adenohypophysis. In order to clarify and quantify the suppressive potency of DMPA and obtain precise information on its mechanism of action, pituitary stimulation tests with gonadotropin releasing hormone (GnRH tests) were performed before and then at 2 and 6 weeks after initiation of therapy. Pituitary response to GnRH remained unaltered, however, at a level corresponding to the decreased basal concentrations, i.e. "LH peaks" dropped by more than 50% (p less than 0.005, Student t-test). The incidence of VMF decreased significantly and remained at a low level until 6 weeks after the administration of DMPA. Treatment with placebo resulted in a slight, but not significant decrease in VMF and did not affect the functional capacity of the adenohypophysis. A remarkable correlation was observed between the reduced size of "LH peaks" and the diminished incidence of VMF. Therefore, evaluation of pituitary response to stimulation with GnRH represents a helpful objective parameter in the assessment of the efficacy of DMPA.

Adult↗
PubMed1983

[Transfer factor as adjuvant immunotherapy in invasive cervix cancer. Report of a double-blind study].

From 1977 to 1982 a prospective randomized double-blind study comparing transfer-factor (TF) versus placebo was conducted in invasive cervical cancer patients after radical surgery and irradiation. The husbands of the cancer patients were selected as leukocyte donors for TF preparations. 60 patients entered the study; 28 patients received placebo and 32 patients received TF. The comparability of both collectives was excellent concerning age and tumor stage. One patient treated with TF died intercurrently. The rate of recurrence of cancer was 5 in the 31 TF-treated patients and 11 in the 28 patients receiving placebo, which was significantly different (p less than 0,05). This difference was even greater when only patients treated for at least 3 months were compared (3 recurrences in the TF-group and 11 recurrences in the placebo-group). Further aspects of this clear clinical results are discussed.

Adult↗
PubMed1983

[The importance of hormone receptor analysis for diagnosis and therapy of gynecologic malignancies].

Determination of the tissue concentration of hormone receptors in gynaecological malignancies has achieved a great importance over the past few years. In carcinoma of the breast this not only constitutes an excellent prognostic parameter, receptor-positive cases usually having a much better prognosis, but also reliably predicts the response to endocrine treatment: the higher the receptor concentration, the higher the remission incidence under hormonal treatment. With regard to the response to chemotherapeutic treatment the predictive value of receptor determinations is still a matter of dispute. In both carcinoma of the breast and carcinoma of the endometrium there is a good correlation between the degree of differentiation and the concentration of receptors. Since the response to treatment with progestational agents depends on the concentration of progesterone receptors, induction of this receptor by means of antioestrogenic medication can be used therapeutically. In ovarian carcinoma a similar distribution of hormone receptors is found. Whether receptor concentration in ovarian carcinoma is related to prognosis and response to endocrine treatment is still under investigation. It can be assumed that determination of hormone receptor concentrations will become an integral part of the management of gynaecological malignancies.

Breast Neoplasms↗
PubMed1983

[Intraoperative lymphoscintigraphy in radical surgery of cancer].

The use of a gamma-camera operating table and the intraoperative lymphoscintigraphy using 99mTc-Antimony sulfide in radical surgery of carcinoma of the breast allows a better control of axillary lymphadenectomy. Remained lymph nodes are localized by an indicator filled with technetium and removed secondarily. Due to this technique it is possible to control and increase the extent of the axillary lymphadenectomy. Since the introduction of intraoperative axillary lymphoscintigraphy 83 patients were treated by mastectomy and axillary lymphadenectomy. In 48 cases complete lymphadenectomy could be obtained.

Antimony↗
PubMed1983

Estrogen - and gestagen - receptors in ovarian carcinoma.

Estrogen (ER) - and progestagen (PgR) - receptors were estimated by a DCC method using Scatchard plot analysis In tissue samples of 68 patients with ovarian carcinomas. The mean ER and PgR levels were at 52 and 74 fmol/mg cytosol protein, respectively. ER+ PgR+ records were noted in 32.4%, ER+ PgR- in 26.4%, ER- PgR+ in 7.4%, and 33.8% presented with ER- PgR-. In the surviving group 44.1% had Er+ PgR+, whereas the patients who died had an incidence of only 20.5% ER+ PgR+. In addition, the incidences of ER+ PgR+ in stage I plus II and stage III plus IV patients were 42.6 and 29.5%, respectively. Furthermore, higher incidences of ER+ PgR+ were recorded in patients older than 60 years of age (63%) than in younger subjects (36%). The present data combine to suggest that receptor assays should become a useful tool in the management of patients bearing ovarian carcinomas. In addition, ER and PgR determinations provide a prognostic index and may improve the possibility to predict which well-differentiated stage I ovarian carcinomas are likely to recur.

Female↗